Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in
moderate to severe refractory ulcerative colitis (UC) patients followed by a maximum of
12-week open-label efficacy and safety study in responders.